VIDEO: Teclistamab 'encouraging' in relapsed or refractory multiple myeloma
Click Here to Manage Email Alerts
Teclistamab, a bispecific IgG4 antibody, was well-tolerated and showed encouraging efficacy with durable, deepening responses in heavily-pretreated, relapse or refractory patients with multiple myeloma, Amrita Y. Krishnan, MD, FACP, told Healio in a video interview.
The overall response rate in the 40 patients treated at the recommended phase 2 dose was 65%. Krishnan, director of Judy and Bernard Briskin Multiple Myeloma Center and professor of hematology/hematopoietic cell transplantation at City of Hope Cancer Center, presented the phase 1 data at the virtual ASCO Annual Meeting.
“We didn’t just see responses, but deep responses, with 58% of patients getting very good partial responses,” Krishnan said.
Krishnan added that it was “encouraging” to see not only a high response rate and deep responses, but also that the responses appear durable.
“My abstract showed very encouraging results as to the safety, efficacy and tolerability of teclistamab,” she said.
Collapse
Krishnan AY, et al. Abstract 8007. Presented at: ASCO Annual Meeting (virtual); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts